Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood Cells, Molecules & Diseases|January 23, 2013
Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac deathAurelio Maggio, Angela Vitrano, Giuseppina Calvaruso, et al.
Acta Bio-Medica : Atenei Parmensis|July 2, 2021
The Prevalence of glucose dysregulations (GDs) in patients with β-thalassemias in different countries: A preliminary ICET-A surveyVincenzo De Sanctis, Ashraf Soliman, Ploutarchos Tzoulis, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 15, 2020
A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A ExperienceVincenzo De Sanctis, Ashraf T Soliman, Shahina Daar, et al.
British Journal of Haematology|February 25, 2009
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trialAurelio Maggio, Angela Vitrano, Marcello Capra, et al.
Hemoglobin|May 24, 2011
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patientsGaetano Restivo Pantalone, Aurelio Maggio, Angela Vitrano, et al.
Acta Bio-Medica : Atenei Parmensis|October 4, 2019
Marital status and paternity in patients with Transfusion- Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countriesVincenzo De Sanctis, Ashraf T Soliman, Ihab El-Hakim, et al.
Endocrine|December 20, 2019
Evaluation of endocrine complications in beta-thalassemia intermedia (β-TI): a cross-sectional multicenter studyMehran Karimi, Tahereh Zarei, Sezaneh Haghpanah, et al.
Haematologica|January 7, 2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohortMaddalena Casale, Gian Luca Forni, Elena Cassinerio, et al.
Blood Cells, Molecules & Diseases|February 24, 2009
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and HemoglobinopathiesAurelio Maggio, Angela Vitrano, Marcello Capra, et al.
Acta Bio-Medica : Atenei Parmensis|September 14, 2020
A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we standVincenzo De Sanctis, Duran Canatan, Joan Lluis Vives Corrons, et al.
Pageof 4